BACKGROUND: Heart failure (HF) disease management programs have shown impressive reductions in hospitalizations and mortality, but in studies limited to short time frames and high-risk patient populations. Current guidelines thus only recommend disease management targeted to high-risk patients with HF. METHODS: This study applied a new technique to infer the degree to which clinical trials have targeted patients by risk based on observed rates of hospitalization and death. A Markov model was used to assess the incremental life expectancy and cost of providing disease management for high-risk to low-risk patients. Sensitivity analyses of various long-term scenarios and of reduced effectiveness in low-risk patients were also considered. RESULTS: The incremental cost-effectiveness ratio of extending coverage to all patients was $9700 per life-year gained in the base case. In aggregate, universal coverage almost quadrupled life-years saved as compared to coverage of only the highest quintile of risk. A worst case analysis with simultaneous conservative assumptions yielded an incremental cost-effectiveness ratio of $110,000 per life-year gained. In a probabilistic sensitivity analysis, 99.74% of possible incremental cost-effectiveness ratios were <$50,000 per life-year gained. CONCLUSIONS: Heart failure disease management programs are likely cost-effective in the long-term along the whole spectrum of patient risk. Health gains could be extended by enrolling a broader group of patients with HF in disease management.
BACKGROUND:Heart failure (HF) disease management programs have shown impressive reductions in hospitalizations and mortality, but in studies limited to short time frames and high-risk patient populations. Current guidelines thus only recommend disease management targeted to high-risk patients with HF. METHODS: This study applied a new technique to infer the degree to which clinical trials have targeted patients by risk based on observed rates of hospitalization and death. A Markov model was used to assess the incremental life expectancy and cost of providing disease management for high-risk to low-risk patients. Sensitivity analyses of various long-term scenarios and of reduced effectiveness in low-risk patients were also considered. RESULTS: The incremental cost-effectiveness ratio of extending coverage to all patients was $9700 per life-year gained in the base case. In aggregate, universal coverage almost quadrupled life-years saved as compared to coverage of only the highest quintile of risk. A worst case analysis with simultaneous conservative assumptions yielded an incremental cost-effectiveness ratio of $110,000 per life-year gained. In a probabilistic sensitivity analysis, 99.74% of possible incremental cost-effectiveness ratios were <$50,000 per life-year gained. CONCLUSIONS:Heart failure disease management programs are likely cost-effective in the long-term along the whole spectrum of patient risk. Health gains could be extended by enrolling a broader group of patients with HF in disease management.
Authors: Modele O Ogunniyi; James B Holt; Janet B Croft; Isaac A Nwaise; Henry E Okafor; Douglas B Sawyer; Wayne H Giles; George A Mensah Journal: Am J Med Sci Date: 2012-01 Impact factor: 2.378
Authors: Melissa A Greiner; Bradley G Hammill; Gregg C Fonarow; David J Whellan; Zubin J Eapen; Adrian F Hernandez; Lesley H Curtis Journal: Am J Cardiol Date: 2011-12-10 Impact factor: 2.778
Authors: Alexander Goehler; Benjamin P Geisler; Jennifer M Manne; Beate Jahn; Annette Conrads-Frank; Petra Schnell-Inderst; G Scott Gazelle; Uwe Siebert Journal: Pharmacoeconomics Date: 2011-09 Impact factor: 4.981
Authors: Yanhong Li; Matthew P Neilson; David J Whellan; Kevin A Schulman; Wayne C Levy; Shelby D Reed Journal: J Card Fail Date: 2013-05 Impact factor: 5.712